Physician profile
Clesheree Stepter
NPI 1871866830
$9,813.70
in general payments reported to CMS, 2019-2025
53 companies · $3,160 in 2025
The $3,160 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $826 · 2022: $1,705 · 2023: $2,022 · 2024: $2,100 · 2025: $3,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,871 · Education: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,871.33 |
| Education | $410.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $975.49 | 2022-2025 | Onureg, Breyanzi, Pomalyst |
| Astellas Pharma US INC | $708.01 | 2021-2025 | Xospata, Vyloy |
| Janssen Biotech, INC. | $678.13 | 2021-2025 | Darzalex, Tecvayli, Carvykti |
| Takeda Pharmaceuticals U.S.A., INC. | $546.54 | 2021-2025 | Ninlaro, Livtencity, Iclusig |
| Incyte Corporation | $406.58 | 2021-2025 | Jakafi, Monjuvi, Niktimvo |
| Daiichi Sankyo INC. | $363.09 | 2022-2025 | Vanflyta, Injectafer |
| Astrazeneca Pharmaceuticals LP | $358.73 | 2021-2025 | |
| Karyopharm Therapeutics INC. | $358.01 | 2021-2025 | Xpovio |
| Glaxosmithkline, LLC. | $310.74 | 2022-2025 | Ojjaara, Blenrep |
| Abbvie INC. | $302.11 | 2022-2025 | |
| Amgen INC. | $283.39 | 2021-2023 | Kyprolis, Blincyto |
| Lilly USA, LLC | $265.22 | 2022-2025 | Jaypirca |
| Sobi, INC | $254.34 | 2022-2025 | |
| Pfizer INC. | $245.51 | 2022-2025 | |
| Servier Pharmaceuticals LLC | $215.74 | 2021-2025 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Legend Biotech USA INC. | $214.12 | 2025 | Carvykti |
| Pharmacyclics LLC, An Abbvie Company | $207.63 | 2021-2023 | Imbruvica |
| Rigel Pharmaceuticals, INC. | $199.93 | 2022-2024 | Rezlidhia, Tavalisse |
| Beigene USA, INC. | $175.03 | 2021-2024 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $159.95 | 2021-2025 | Breyanzi |
| Genentech USA, INC. | $157.14 | 2022-2025 | Venclexta, Columvi, Lunsumio |
| Sanofi-Aventis U.S. LLC | $155.10 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $152.00 | 2021-2025 | Prevymis, Zerbaxa, Dificid |
| Jazz Pharmaceuticals INC. | $147.53 | 2021-2024 | |
| Kadmon Pharmaceuticals LLC | $140.65 | 2021 | |
| Taiho Oncology, INC. | $137.49 | 2021-2025 | |
| Blueprint Medicines Corporation | $137.12 | 2022-2025 | Ayvakit |
| Genzyme Corporation | $135.25 | 2021-2025 | |
| Seagen INC. | $115.52 | 2023-2025 | Adcetris |
| Genmab U.S., INC. | $107.42 | 2023-2025 | Epkinly |
| Alexion Pharmaceuticals, INC. | $93.71 | 2022-2023 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $92.15 | 2024-2025 | |
| Beone Medicines USA, INC. | $91.11 | 2025 | Brukinsa |
| Adaptive Biotechnologies Corporation | $91.05 | 2024-2025 | Clonoseq |
| Stemline Therapeutics INC. | $90.53 | 2024-2025 | Elzonris |
| Acrotech Biopharma INC. | $81.40 | 2021-2024 | Beleodaq |
| Cti Biopharma Corp. | $76.88 | 2022-2023 | Vonjo |
| Adc Therapeutics America, INC. | $64.40 | 2022-2023 | |
| Geron Corporation | $58.21 | 2025 | Rytelo |
| Syndax Pharmaceuticals, INC. | $58.10 | 2025 | |
| Morphosys, US INC. | $51.67 | 2022-2023 | Monjuvi |
| Pharmaessentia USA Corporation | $50.65 | 2024-2025 | Besremi |
| Dova Pharmaceuticals | $45.61 | 2021 | |
| Kyowa Kirin, INC. | $42.46 | 2024-2025 | Poteligeo |
| Kite Pharma, INC. | $37.64 | 2025 | Yescarta |
| Apellis Pharmaceuticals, INC. | $37.55 | 2022-2023 | Empaveli |
| Invivyd INC | $23.16 | 2024 | Pemgarda |
| Azurity Pharmaceuticals, INC. | $22.00 | 2025 | Danziten |
| Tersera Therapeutics LLC | $21.64 | 2025 | Quzyttir |
| Ipsen Biopharmaceuticals, INC | $19.69 | 2025 | Onivyde |
| Tempus Ai, INC | $19.00 | 2025 | Xt Cdx |
| Recordati_rare_diseases_inc. | $16.48 | 2025 | Sylvant |
| Secura Bio, INC. | $15.10 | 2025 | Copiktra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clesheree Stepter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.